In this research article, the synthesis, structural characterization, and biological, DNA binding and anticancer properties of pyrimidine incorporated Schiff base ligand L and its [CuL 2 ](ClO 4 ) 2 (1) and [ZnL 2 ](ClO 4 ) 2 (2) complexes are reported. The isolated complexes 1 and 2 have significant antibacterial and antifungal properties, greater than those of ligand L. The interaction between protein and L were analyzed by an in silico method. The intercalative binding of the prepared compounds was proved from electronic absorption, fluorometric, cyclic voltammetric and viscometric methods. The calculated binding parameters such as, K b (2.65×10 3 , L; 7.74×10 3 , 1 and 2.99×10 3 , 2); K sv (3.30×10 3 , L; 4.31×10 3 , 1 and 3.89×10 3 , 2), and K app (2.15×10 5 , L; 3.30×10 5 , 1 and 2.82×10 5 , 2) indicted that complex 1 has better interaction ability than L and complex 2. The in vitro anticancer properties of L, and complexes 1 and 2 against human cancer (MCF-7, HeLa and HEp-2) and normal (NHDF) cell lines were determined by the MTT assay method. The obtained results designated that complexes 1 and 2 exhibited substantial anticancer activity against the cancer cell lines, better than that of L.
INTRODUCTION
Pyrimidine is a heterocyclic compound and it forms the backbone of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Pyrimidine derivative drugs reveal various pharmacological and biological activities, such as, antitumor, 1,2 antiamoebic, 3 antimalarial, 4, 5 antipneumocystis carinii pneumonia 6 and antimicrobial. 2, 7, 8 Moreover, the attachment of CF 3 groups results in compounds that are lipophilically and pharmacologically more active than the corresponding non--fluorinated compounds. These -CF 3 -substituted organic compounds have various biological competences, such as, herbicidal, fungicidal, analgesic, antihyperglycemic and antipyretic, etc. [9] [10] [11] [12] [13] Pyrimidine-containing drugs, such as gefitinib, erlotinib and afatinib were used in cancer-related treatments. 14 Therefore, Schiff base ligands were prepared from biologically and pharmacologically active pyrimidine derivative compounds. These Schiff base ligands possess analytical, biological and pharmacological applications. 15 In earlier days, Schiff bases were employed to develop metal-based complexes 16, 17 because metal complexes acquire diverse biological abilities, such as antidiabetic, antimicrobial, antioxidant, DNA cleavage or binding and anticancer activities. [18] [19] [20] Especially, copper(II) and zinc(II) complexes were synthesized with much more interest due to their enhanced biological applications. [21] [22] [23] The interest in the biological properties of copper(II) and zinc(II) complexes has been continued in the present study through incorporation of a bio-active pyrimidine ligand. The formations of L, and complexes 1 and 2 were confirmed from analytical, spectroscopic and theoretical techniques. Moreover, their biological properties, such as antimicrobial, DNA binding and in vitro anticancer activities were studied.
EXPERIMENTAL

Materials and methods
4-(4-Morpholinyl)benzaldehyde, 2-hydrazino-4-(trifluoromethyl)pyrimidine, Tris-HCl, sodium chloride and ethidium bromide were procured from Sigma Aldrich. Cu(ClO 4 ) 2 ·6H 2 O and Zn(ClO 4 ) 2 ·6H 2 O were received from Alfa Aesar company. Calf thymus (CT) DNA was purchased from GeNei Bangalore, India. Elemental analyses were realized on an Elementar Vario EL III analyzer. FTIR and NMR spectra were recorded using an FTIR Affinity-1 Shimadzu instrument and Bruker (400 and 125 MHz) spectrometers. The mass spectra were obtained on an ESI-MS spectrometer. The ESR spectra were recorded at 300 and 77 K in an IIT, Mumbai. Cyclic voltammetric studies were recorded on a CHI650C instrument. The absorption and fluorescence spectra were recorded on a UV-1800 Shimadzu spectrophotometer and FluoroMax-4 spectrometer, HORIBA, respectively.
Analytical and spectral data are given in Supplementary material to this paper.
Synthesis of ligand L
Ligand L was synthesized by refluxing 4-(4-morpholinyl)benzaldehyde (0.1912 g, 1 mmol) with 2-hydrazino-4-(trifluoromethyl)pyrimidine (0.1781 g, 1 mmol) in 25 mL of ethanol for 6 h. The resulting solution was slowly evaporated on a water bath. The yellow col-PYRIMIDINE INCORPORATING METAL(II) COMPLEXES 279 oured product was collected by filtration and washed with 10 mL of cold methanol and recrystallized from hot chloroform.
Synthesis of complexes 1 and 2
An ethanolic solution of ligand L (2 mmol) was mixed with metal perchlorates (1 mmol) in 10 mL of ethanol maintaining a metal : ligand ratio of 1 : 2. The resulting solution was refluxed under stirring for 5 h. Then the solution was evaporated on a water bath, the precipitated solid filtered and washed thoroughly with 10 mL of petroleum ether and dried in vacuo over CaCl 2 .
Computational studies
Density functional theory (DFT) calculations were performed with the hybrid exchange--correlation function using the 6-311G(d,p) and LANL2DZ basis set by the Gaussian 09 program to understand the mode of complexation between the ligand and its complexes. 24 Initially, the optimized geometries of both the ligand and its complexes were determined by the B3LYP functional but using 6-311G(d,p) and LANL2DZ basis set, respectively.
Antimicrobial studies
The antimicrobial activity of the prepared compounds were screened against the bacterial species, Escherichia coli, Klebsiella pneumoniae, Pseudomonas fluorescens, Shigella sonnei and Staphylococcus aureus, and the fungal species, Aspergillus niger, Candida albicans, C. tropicalis, Mucor indicus and Rhizopus by the well diffusion method. 21 The reference drugs streptomycin and amphotericin were used for the antibacterial and antifungal studies, respectively.
Anticancer studies
The anticancer capabilities of ligand L, complexes 1 and 2 against various cancer cell lines (MCF-7, breast adenocarcinoma; HeLa, cervical, HEp-2, laryngeal) and a single normal cell line (NHDF, normal human dermal fibroblasts) were performed by the MTT assay 25 :
Absorbance of sample Inhibition, % 100 100 Absorbamce of control = −
Protein-ligand docking
The docking of ligand L with protein was studied by a previously reported method. 26 The prepared proteins and ligand L were docked using the LibDock module of Accelrys Discovery Studio software, version 2.1, to acquire the drug with protein interaction.
DNA interaction
The CT-DNA interaction of ligand L and complexes 1 and 2 in 5 mM and 50 mM TrisHCl buffer solution, respectively, under physiological conditions were appraised using absorption spectroscopy and fluorescence, cyclic voltammetric and viscometric measurements. [27] [28] [29] 
RESULTS AND DISCUSSION
The synthetic route to ligand L, and complexes 1 and 2 are depicted in Schemes 1 and 2, respectively. The ligand L (4-(4-morpholinyl)benzaldehyde, 2--[4-(trifluoromethyl)-2-pyrimidinyl]hydrazone) is lemon yellow in colour and well soluble in acetone, acetonitrile, DMSO and DMF solvents. The complexes 1 and 2 are brown and dark brown colour and soluble in DMSO and DMF solvents. The molar conductance at infinite dilution (Λ m ) of complexes 1 and 2 in DMSO was found at 104 Ω -1 cm 2 mol -1 for complex 1 and 109 Ω -1 cm 2 mol -1 for complex 2, which signified them to be electrolytes. Moreover, the obtained conductance values confirmed that percholarate ions are present in the outside coordination sphere of complexes 1 and 2. In the 1 H-NMR spectra of complex 2, the signals of the azomethine (-CH=N-) and pyrimidine moiety protons (=CH-N=) appeared at 8.64 (1H, s) and 8.83 (1H, d), respectively. These spectral results reveal that the azomethine and pyrimidine nitrogen atoms participate in the complexation. As per comparison with the free ligand L, the signals of the pyrimidine (-CH=C-CF 3 and -NH), aromatic and morpholine (mor-CH 2 -N-CH 2 -and mor-CH 2 -O-CH 2 -) protons remained more or less at the same positions in complex 2.
The 13 C-NMR spectra of ligand L and complex 2 were taken in DMSO-d 6 solution and the obtained data are given in the Supplementary material. In the spectra of ligand L, the azomethine (-CH=N), pyrimidine C 2 and C 6 appeared at 138.60, 160.61 and 153.60 ppm, respectively. In complex 2, these peaks appeared at 139.45, 161.10 and 154.16 ppm, respectively. These results indicate that ligand L formed coordinate bonds with the central metal atom via azomethine and pyrimidine ring (C 2 ) nitrogen atoms.
FT-IR spectra
The FT-IR spectrum of ligand L showed a characteristic band at 1544 cm -1 due to ν(-CH=N) stretching vibrations. 30 The bands at 1591, 1465 and 1402 cm -1 are associated with ν(-NH) and ν(=CH-N=) aromatic ring nitrogen stretching vibrations, respectively. In the spectra of complexes 1 and 2, characteristic bands appeared at 1522 (1) and 1535 cm -1 (2), and 1388 (1) and 1384 cm -1 (2), which are due to ν(CH=N) and ν(aromatic, =CH-N=) group vibrations. This result indicates that nitrogen atoms of azomethine ν(CH=N) and the pyrimidine ring ν(aromatic, =CH-N=) participated in the complexation. Bands are observed at 1087 and 1088 cm -1 in complexes 1 and 2, respectively, due to the presence of perchlorates in the outer coordination spheres.
Mass spectra
In the ESI-MS spectrum of ligand L, the molecular ion peak was observed at m/z 350.9 and daughter peaks were observed for C 12 H 7 N 4 F 3 + , C 6 H 5 N 4 F 3 + and C 5 H 4 N 3 F 3 + . In complexes 1 and 2, molecular ion peaks were obtained at m/z, 765 (1) and 767 (2) . These values evidence that one mole of complex 1 or 2 contained with two moles of ligand L.
Electronic absorption spectra
In the UV-Vis spectra of ligand L, and complexes 1 and 2, bands were observed at 266 and 336 nm owing to π→π* and n→n* transitions of ligand L. 31 The ligand to metal charge transfer (LMCT) spectra of complexes 1 and 2 showed bands at 272 and 329 nm for complex 1 and 270 and 338 nm for complex 2. In the UV-Vis spectrum of complex 1, a broad band was displayed at 777 nm and the band assignments are 2 B 1g → 2 A 1g , 2 B 1g → 2 B 2g and 2 B 1g → 2 E g transitions in a square planar arrangement. 32 Complex 2 possess d 10 electronic configuration, which authenticates the absence of a d-d transition, and therefore complex 2 showed INCT bands at 270 and 338 nm, which confirms the complexation.
ESR spectra
ESR spectral data give knowledge of the environment of a metal ion. The ESR spectrum data of complex 1 recorded in DMSO at liquid nitrogen temperature gave g II and g I values of 2.35 and 2.07, respectively. The spectrum of complex 1 showed that g-tensor value are g II > g I > 2.0027, indicating the unpaired electrons lie predominantly in the d x 2-d y 2 orbital, which suggests square planar geometry around the central metal ion. [33] [34] [35] [36] The g II /A II value is useful for predicting the structure of the complex 1 and the value of 154 suggests square planar arrangement of complex 1 around the central metal ion. 37 According to Hathaway and Billing, [38] [39] [40] the G value greater than 4 suggested that the local tetragonal axes are aligned parallel or only slightly misaligned.
Computational studies
The 3D structure of ligand L, and complexes 1 and 2 were optimized using Density functional theory (DFT) calculations accomplished through the (B3LYP/ /6-311G(d,p)/LANL2DZ) basis set using the Gaussian 09 program. 24 The basis set 6-311G(d,p) was used for the N, O, C and H atoms and LANL2DZ was exploited for complexes 1 and 2. In ligand L, the HOMO is spread over the whole π-moiety, while the LUMO is spread over the pyrimidine and imine moieties. After the introduction of Cu(II), the HOMO is spread over the surrounding of the metal ion and its LUMO is spread on the pyrimidine moiety with little contribution of the metal ion. Similarly, in 2, the HOMO and LUMO are more spread over the pyrimidine moiety and slightly in the morpholine moiety with a metal ion contribution (Fig. 1) . In addition, the calculated HOMO-LUMO energy gap for complexes 1 and 2 was lower than that for the free ligand. The order of the energy band gap is L > 2 > 1. The obtained results obviously indicate that the complexation of Cu(II) and Zn(II) to the ligand L result in a disruption of internal charge transfer, which may be responsible for the appearance of new absorption band in the visible region. 
Biological studies
The pharmacological, DNA binding and in vitro anticancer activities of ligand L, complexes 1 and 2 were studied as follows.
Antimicrobial studies. The antimicrobial activity of ligand L, and complexes 1 and 2 were screened against the bacterial species E. coli, K. pneumoniae, P. fluorescens, S. sonnei and S. aureus, and the fungal species A. niger, C. albicans, C. tropicalis, M. indicus and Rhizopus. The reference drugs streptomycin and amphotericin were used for the antibacterial and antifungal studies, respectively. The zone of inhibition values of isolated compounds are presented in Table I . The obtained results established that the synthesized complexes 1 and 2 acted as better antibacterial and antifungal agents than ligand L due to their chelation ability. 41 Additionally, ligand L, and complexes 1 and 2 show superior activity against E. coli bacteria and C. albicans fungi than against the other pathogens. Anticancer studies. The positive results received from the biological studies encouraged the investigation of the anticancer ability of the pyrimidine incorporated compounds. The in vitro anticancer activities of the ligand L, and complexes 1 and 2 against human cancer cell lines (MCF-7, breast adenocarcinoma; HeLa, cervical; HEp-2, laryngeal) and NHDF (normal human dermal fibroblasts) cell line were examined by using the MTT assay (Fig. S-1) . The 50 % inhibitory concentration (IC 50 , µg mL -1 ) values of the prepared compounds against human normal and cancer cell lines are given in Table II . From the obtained data, cisplatin can affect the cancer as well as normal cell lines at lower concentration (6.93±0.35 µg mL -1 MCF-7; 7.46±0.37 µg mL -1 HeLa; 10.28±0.51 µg mL -1 HEp-2). When compared to the above results, L had no significant anticancer activity against the cancer cell lines or the normal cell lines (75.82±3.79 µg mL -1 MCF-7; 76.26±3.81 µg mL -1 HeLa; 81.03±4.05 µg mL -1 HEp-2). Moreover, the IC 50 values of the complexes 1 and 2 against cancer cell lines revealed that complex 1 has moderate anticancer ability on MCF-7 (54.51±2.73 µg mL -1 ) and on HeLa (55.40±2.77 µg mL -1 ) cell lines which was not so obvious on the HEp-2 cell line (77.57±3.88 µg mL -1 ). However, complex 2 expressed modest anticancer activities on all three selected cancer cell lines (58.89±2.94 µg mL -1 , MCF-7; 59.98±2.99 µg mL -1 , HeLa; 60.79±3.04 µg mL -1 , HEp2). From these observations, the pyrimidine incorporated complexes 1 and 2 could control the growth of cancer cells. 
Protein-ligand interaction
The mode of interaction of ligand L with antioxidant enzymes and the estrogen receptor alpha was analyzed using molecular docking studies. From the various obtained docked poses, the best pose was chosen based on the higher absolute energy and the LibDock score. The protein-ligand interaction was found to be stronger in the presence of hydrogen bond interactions, especially with bond length less than 0.3 nm (Table III) . 42, 43 The present study also revealed the presence of H-bond interaction between ligand L and the proteins indicating a better protein-ligand interaction. Binding of ligand L with the antioxidant enzymes and the estrogen receptor alpha predicts the mode of action through which the compound acts as an anticancer agent by regulating their involvement in cancer progression. 
DNA binding
Absorption titration. The interaction between the compounds and CT-DNA was ascertained by electronic absorption spectroscopy. The absorption spectra of complexes 1 and 2 (50 µM) in the presence and absence of CT-DNA (0-50 µM)
were assessed by typical absorption spectral titrations (Fig. 2a and b) . As shown in Fig. 2a and 2b , the incremental addition of CT-DNA to solutions of complex 1 and 2 led to hypochromism (6.27, L; 15.60, 1 and 13.57, 2) with bathochromic shifts of 3-6 nm. These observed spectral titration results clearly indicate that complexes 1 and 2 can bind with CT-DNA through intercalative interaction due to the presence of the pyrimidine substituent. In order to determine the intrinsic binding constants (K b ) of the prepared compounds, the following equation 25 was used:
where c DNA is the concentration of CT-DNA. intercalation with the base pairs. The binding strengths of the studied compounds with DNA show that complex 1 has a higher binding affinity as compared to ligand L and complex 2, in the following order: 1 > 2 > L.
Competitive binding. The fluorescence spectra of EB-DNA in the presence of the prepared compounds are presented in Fig. 3 . As shown in Fig. 3a and b , the concentration of complexes 1 and 2 enlarges to the EB-DNA, the fluorescence intensity of the complexes 1 and 2 steadily decreases. These results confirm that competitive interactions occurred. The intercalative binding of ligand L, complexes 1 and 2 with EB-DNA could be summarized by the Stern-Volmer equation: 44 I 0 /I = 1 + K sv c Q
where I and I 0 are the emission intensities in the presence and absence of the quenchers (ligand L, complexes 1 and 2), respectively, K sv is the linear Stern--Volmer quenching constant and c Q is the concentration of the quencher. The K sv values were obtained from the slope of plots of I 0 / I vs. c Q (Fig. 3) . Additionally, the binding affinity (K app ) of ligand L complexes 1 and 2 in contrast to that of EB was evaluated using the following equation: 45 K EB c EB = K app c complex ( 4 ) where, c complex is the concentration of the newly prepared compounds necessary for a 50 % reduction in the fluorescence intensity of EB and K EB = 1.0×10 7 . The binding constant (K sv ) and binding affinity (K app ) values of the present compounds are given in Table V 
Electrochemical studies
The results of cyclic voltammetric measurements of complexes 1 and 2 in the presence and absence of CT-DNA (0-50 µM) are presented in Fig. 4a and b. Here, as the concentration of CT-DNA rises, the cathodic and anodic peak currents of the prepared complexes 1 and 2 increase, and their peak potentials are shifted to negative values. These findings confirm that the newly prepared compounds can interact with CT-DNA.
Viscosity measurements
The viscometric studies were very useful in the clarification of the nature of the binding of the synthesized compounds to CT-DNA. The graphs of the relative viscosity vs. c complex /c DNA are presented in Fig. 5 . As the concentration of compounds increases, the viscous flow of CT-DNA increases. These results correlate with the spectroscopic and cyclic voltammetric results that suggested the prepared compounds should interact with CT-DNA through an intercalation mode. )). Ове вредности показују да комплекс 1 има бољу интеркалациону способ-ност везивања за ДНК у односу на лиганд L и комплекс 2. In vitro антиканцерска својства лиганда L и комплекса 1 и 2 према хуманим ћелијама тумора (MCF-7, HeLa и HEp-2) и нормалним (NHDF) ћелијским линијама одређена су помоћу MTT методе. Добијени резултати су показали да комплекси 1 и 2 показују значајно већу активност према ћелијама канцера у односу на лиганд L.
(Примљено 6. јуна, ревидирано 7. августа, прихваћено 5. септембра 2018)
